Inclusion Criteria:

          1. Must be able to understand and voluntarily sign an informed consent form

          2. Must be able to adhere to the study visit schedule and other protocol requirements

          3. Male or female, age 18 years or older

          4. Life expectancy of > 6 months.

          5. Must have a in R1 and R2 relapse Multiple Myeloma with a measurable disease :

               -  1 to maximum 2 lines of therapy prior to study entry

               -  Relapse Refractory or primary refractory or relapse

               -  Must have received prior treatment with a Lenalidomide-containing regimen for at
                  least 2 consecutive cycles

          6. Must have measurable disease as defined by the following: must have a clearly
             detectable and quantifiable monoclonal M-component value in the serum and/or urine :

               -  IgG/IgA (serum M-component > 5g/l),

               -  Light chain (serum M-component >1g/l or Bence Jones > 200mg/24H),

               -  Serum FLC assay (including for IgD isotypes): involved FLC level > 10 mg/dl
                  provided serum.

             FLC ratio is abnormal for patients not measurable on any of the 3 above criteria.

          7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

          8. Wash out period without MM treatment must be of 28 days minimum before C1D1, except
             for anti CD-38 (See exclusion criteria#10).

          9. Adequate bone marrow function, documented within 72 hours and without transfusion 72
             hours prior to the first intake of investigational product (C1J1) with no growth
             factor support (one week), defined as :

               -  Absolute neutrophils ≥ 1 x109/L,

               -  Untransfused Platelet count ≥ 75 x109/L,

               -  Hemoglobin ≥ 8.5 g/dL.

         10. Adequate organ function defined as :

               -  Serum total bilirubin < 2x upper limit of normal (ULN),

               -  Clearance creatinine ≥ 30ml/min,

               -  Serum SGOT/AST or SGPT/ALT < 3x upper limit of normal (ULN).

         11. Patients affiliated to an appropriate social security system.

         12. A man who is sexually active with a pregnant female or a FCBP* must agree to use a
             barrier method of birth control eg, condom with spermicidal
             foam/gel/film/cream/suppository, even if he has had a vasectomy. All men must also not
             donate sperm, spermatozoa during the study, for 5 months following treatment
             discontinuation.

         13. A woman FCBP* must understand and agree to use 2 reliable effective methods (a very
             effective method and an effective additional method) of contraception simultaneously
             without interruption :

               -  For at least 28 days before starting experimental treatments,

               -  Throughout the entire duration of experimental treatments,

               -  During dose interruptions,

               -  And for at least 5 months after the last dose of experimental treatments.

         14. All patients must agree to not donate blood during the treatment period, interruptions
             of treatment and at least 5 months after the last dose of treatment.

         15. All patients must understand and accept to comply with the conditions of the
             Pomalidomide pregnancy prevention plan (Appendix of the protocol).

        Exclusion Criteria:

          1. Any other uncontrolled medical condition or comorbidity that might interfere with
             patient's participation, including simultaneous participation to another
             interventional clinical study.

          2. Known positive for HIV or active infectious hepatitis, type B or C.

          3. Patients with non-secretory MM and non-measurable MM

          4. Patient with terminal renal failure that require dialysis or clearance creatinine < 30
             ml/min (calculated with MDRD formula)

          5. Any uncontrolled or severe cardiovascular or pulmonary disease determined by the
             investigator including :

               -  NYHA functional classification III or IV congestive heart failure

               -  LVEF (Left Ventricular Ejection Fraction) < 40%

               -  Uncontrolled angina, hypertension or arrhythmia

               -  Myocardial infarction in the past 6 months

          6. Prior history of malignancies, other than multiple myeloma, unless the patients has
             been free of the disease for ≥ 5 years. Exceptions include the following:

               -  Basal or squamous cell carcinoma of the skin

               -  Carcinoma in situ of the cervix or breast

               -  Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)

          7. Evidence of central nervous system (CNS) involvement

          8. Ongoing active infection or other clinically significant uncontrolled cardiovascular
             events

          9. Unable to comply with IMids regulation to thromboprophylaxis, or teratogenic
             recommandations.

         10. Refractory to prior to anti CD38.Patients can be exposed to anti CD38 (any), BUT the
             wash out period for patient pre-treated with an anti CD38 antibody must be of 4,5
             months minimum between last dose of previous anti-CD38 antibody and the first dose of
             isatuximab.

         11. Refractory to prior carfilzomib

         12. Known allergy to one of the study product (pomalidomide, isatuximab, carfilzomib) or
             dexamethasone

         13. Patient with a history of severe allergic reactions to thalidomide or lenalidomide

         14. Exposed to pomalidomide

         15. Known intolerance to infused protein products, sucrose, histidine, and PS80

         16. Contraindications to dexamethasone

         17. Any ongoing non hematological adverse event or medical history grade> 2 severity

         18. Pregnant or breast-feeding females

         19. Refusal to participate in the study

         20. Persons protected by a legal regime (guardianship, trusteeship)